What's in zhang li's pipeline?

zhang li has 1 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with zhang li's portfolio?

Top competitors by shared drug class: Amarantus BioScience Holdings, Inc., CUTISS AG, Massachusetts General Hospital.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/zhang-li.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

zhang li — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

zhang li pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Orthopedics, Wound care · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Amarantus BioScience Holdings, Inc. · 1 shared drug class
CUTISS AG · 1 shared drug class
Massachusetts General Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for zhang li:

Cite this brief

Drug Landscape (2026). zhang li — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/zhang-li. Accessed 2026-05-16.